Novel DprE1 inhibitor, killing M. tuberculosis

Substrate of CYP3A and inhibitor of P-glycoprotein

Novel selective DPP8/9 inhibitor, blocking AML progression in vivo

Novel inhibitor of dipeptidyl peptidase 7 (DPP7)

Novel highly selective agonist for the δ-opioid receptor, producing less convulsions than most drugs from this family and having antidepressant-like effects

First Potent Small Molecule Ligand for MALAT1

Novel Dual PROTAC for Simultaneous Degradation of EGFR and PARP

Novel boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors

Novel 2-aminoethyl diphenylborinate (2-APB) analogue, inducing a profound activation of SOCE in DT40 cells, albeit at low concentrations (10 nM), blocking the melatonin-induced [Ca ] cyt increase and SOCE in P. falciparum.

Novel effective and selective inhibitor of E. coli topoisomerase I

Novel antibacterial with activity against the Gram-negative bacteria associated with nosocomial infections

Agonist of GABAA receptors α15 subunits

Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects

Anthelmintic, for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle

Dual orexin receptor antagonist (OX1R and OX2R antagonist or DORA)

Selective MAO-B inhibitor

Analeptic agent, stimulating central nervous system; Anti-barbiturate-overdose

Novel antitubercular and antiparasitic agent, possessing excellent in vitro activity against both L. donovani and Leishmania infantum as well as displaying a better safety profile

Novel potentiator of β-lactam activity against Gram positive and Gram negative pathogens

Novel DNA primase inhibitor

Novel DNA primase inhibitor

Novel,orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor

Potent and highly selective µ opioid agonist

Novel inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells

Novel cell permeable caged Luciferin

Novel potent and selective PROTAC degrader of myeloid cell leukemia 1 (MCL1)

Novel non-nucleoside inhibitor of Zika viral RNA-dependent RNA polymerase (RdRp) enzymes

Novel blocker of the TLR2 and TLR4 downstream signaling pathway, effectively inhibiting mRNA expression of MyD88 and p65, major subunit of nuclear factor-kappaB

Novel antineoplastic agent, exhibiting remarkable anticancer activity as well as excellent cellular selectivity

Novel multi-target anticancer prodrug activated by the tumor specific CYP1B1 enzyme, potently inhibiting HCT-15, HCT-116 and K562 cells growth, showing moderate anti-proliferative activity towards MDA-MB-231, HepG2, PANC, Bel7402 and MGC803 cancer cells,